Please login to the form below
Shionogi
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shionogi's 2012 Japan sales performance.
Gilead bags EU approval for next-generation HIV drug
ViiV - a joint venture between GlaxoSmithKline (GSK), Pfizer and Shionogi - has been making headway in the market with its Triumeq (abacavir, lamivudine and dolutegravir) and Tivicay (dolutegravir) brands, which have been
Pharma's reputation rises, but pricing still a sore point
Once again, PatientView also looked at individual pharma companies' reputations and the poll revealed that ViiV Healthcare - the HIV-focused joint venture between GlaxoSmithKline (GSK), Pfizer and Shionogi - was once again
Rare disease therapies head the ‘class of 2015’
Shionogi. Japan. mepolizumab. Nucala. severe eosinophilic asthma. anti-interleukin-5 antibody. GlaxoSmithKline. USA.
Gilead wins US approval for second TAF-based HIV drug
between GlaxoSmithKline (GSK), Pfizer and Shionogi.
ViiV and Janssen take long-acting HIV regimen into phase III
Now ViiV - a joint venture between GlaxoSmithKline, Pfizer and Shionogi - has confirmed it intends to take the combination into phase III testing later this year.
[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- Rare diseases: not so rare after all
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
